Denis A. Maksaev

Denis A. Maksaev

Auto-generated profile, based on publicly available information

Denis A. Maksaev

Ryazan State Medical University named after academician I.P. Pavlov, Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Closed access
PDF file
RKRoman E. Kalinin
Roman E. Kalinin
ISIgor Suchkov
Igor Suchkov
DMDenis A. Maksaev
Denis A. Maksaev
AIM: This study aimed to investigate the effectiveness of the application of a combination of the preparation of micronized purified flavonoid fraction (MPFF) and elastic compression in patients with acquired lymphostasis. MATERIALS AND METHODS: Sixty patients with stage II secondary lower limb lymphedema according to М. Foeldi were included. The patients were divided into two groups through randomization with the envelope method. The first group (n = 30) was subjected to a conservative treatment (MPFF, 1000 mg/day) coupled with elastic compression (3rd class compression stockings). The second group was given compressive therapy (third-class compression stockings). The patients were physically examined through the measurement of the circumference of the limb at different levels. RESULTS: In the first group, the circumference of the lower third of the shin decreased by 8.15% (p = 0.005) after 1 month and by the end of treatment by 10.6% (p 0.001), of the middle third of shin by 3.15% (p = 0.001) and 4.78% (p 0.001), and of the upper thirdby 4.08% (p 0.001) and 5.99% (p 0.001). By the end of the observation period (3 months), the circumference of the lower third of the shin in the second group (29.68 4.67 cm) was significantly greater than that in the first group (26.65 2.92 cm, p = 0.035). No adverse reactions were observed in the MPFF group. CONCLUSIONS: The volume of the lower limbs of patients with acquired lymphedema decreased after using a combination of MPFF and elastic compression to a larger extent than after the isolated use of elastic compression. Patients taking MPFF had a positive clinical effect without adverse reactions. Therefore, MPFF could be used in the pharmacotherapy of secondary lymphedema of the lower limbs.

14 October 2022 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
RKRoman E. Kalinin
Roman E. Kalinin
ISIgor Suchkov
Igor Suchkov
АААндрей Агапов
Андрей Агапов
NMNina Mzhavanadze
Nina Mzhavanadze
DMD. A. Maksayev
D. A. Maksayev
ACA. A. Chobanyan
A. A. Chobanyan
Эффективность компрессионной терапии в профилактике венозных тромбоэмболических осложнений у пациентов с COVID-19

4 October 2024 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
АААндрей Агапов
Андрей Агапов
RKRoman E. Kalinin
Roman E. Kalinin
NMNina Mzhavanadze
Nina Mzhavanadze
VPVladislav O. Povarov
Vladislav O. Povarov
ANAlexander A. Nikiforov
Alexander A. Nikiforov
ЧАЧобанян Артем Александрович
Чобанян Артем Александрович
INTRODUCTION: The physical inactivity, hypoventilation, as well as chronic inflammation in obese patients aggravates their condition in various diseases. These features have become important with the advent of the COVID-19 pandemic, in which inflammation and platelet-activated coagulopathy are closely linked. AIM: To study laboratory parameters of inflammation and platelet apoptosis in obese patients using various types of anticoagulant prophylaxis of venous thromboembolic complications with the underlying COVID-19. MATERIALS AND METHODS: The study included 370 patients with COVID-19. Depending on the presence or absence of obesity and the type of parenteral anticoagulant, patients in our study were divided into groups: group 1 — non-obese + low molecular weight heparin (LMWH) (n = 114), group 2 — non-obese + unfractionated heparin (UFH) (n = 58), group 3 — obesity + LMWH (n = 76), group 4 — obesity + UFH (n = 66). The incidence of venous thromboembolic complications (VTEC), bleeding, general markers of the acute phase of inflammation, and specific markers of platelet apoptosis (phosphatidylserine and calreticulin) have been analyzed. RESULTS: At the end of hospital treatment, a decrease in ferritin levels was noted in patients both with and without obesity receiving LMWH. The concentration of calreticulin was higher in patients taking LMWH (groups 1 and 3). Phosphatidylserine levels were high in patients receiving LMWH only if they were obese. In patients taking UFH compared to LMWH, a high incidence of pulmonary embolism (PE) without a source (13.6% of cases versus 2.6%, respectively, p = 0.029) and PE with a source in the lower extremities (9.1% of cases versus 0%, respectively, p = 0.018) was found. When using LMWH, a lower incidence of bleeding was observed compared to using UFH (5.3% of cases versus 16.7%, respectively, p = 0.056). CONCLUSION: The levels of phosphatidylserine and calreticulin are higher in obese patients receiving LMWH. At the same time, patients in this group have a low incidence of VTEC and hemorrhagic complications compared to the group of patients taking UFH.

17 June 2024 in Journal of Venous Disorders
Verified
Journal Article
Closed access
ISIgor Suchkov
Igor Suchkov
NMNina Mzhavanadze
Nina Mzhavanadze
ASAndrey Shuldyakov
Andrey Shuldyakov
ZTZ.G. Tatarintseva
Z.G. Tatarintseva
NKN.V. Kirichenko
N.V. Kirichenko
NLN.V. Lomakin
N.V. Lomakin
OBJECTIVE To evaluate the effectiveness and safety of a new selective oral factor Xa inhibitor amidine hydrochloride (DD217) as compared to enoxaparin sodium in prevention of venous thromboembolic events (VTE) in patients hospitalized with COVID-19. MATERIAL AND METHODS A multipla-center prospective randomized controlled trial AM217_03 (clinicaltrials.gov identifier NCT05185804) included 401 patients hospitalized with the novel coronavirus infection COVID-19. Patients randomized to group 1 (n=198) received amidine hydrochloride orally at a dose of 60 mg once a day. Patients randomized to group 2 (n=202) received enoxaparin sodium subcutaneously at a dose of 40 mg once daily. The primary end point characterizing the effectiveness was the overall number of cases of thromboembolic events, including VTE. The primary endpoint characterizing safety was the incidence of major and clinically significant non-major bleedings during the study therapy (maximum 30 days). RESULTS The efficacy analysis included data from 177 patients in group 1 and 194 in group 2. No thrombotic events as part of the composite primary endpoint was observed during study therapy in the amidine hydrochloride group and was reported in 7 patients in the enoxaparin sodium group (3.61%; p=0.015). At the same time, the proportion of patients requiring intensive care due to worsening COVID-19 or the occurrence of complications during study therapy was 17 (8.7%) in the amidine hydrochloride group and 10 (5.0%) in the enoxaparin group (p=0.14). No major and clinically significant non-major bleeding was registered in the amidine hydrochloride group compared with 1.0% (2 patients) in the enoxaparin sodium group (p=0.499). CONCLUSION In hospitalized patients with COVID-19 who did not require an intensive care stay, oral factor Xa inhibitor amidine hydrochloride 60 mg once daily was noninferior to subcutaneous enoxaparin sodium 40 mg once daily in preventing thromboembolic complications, demonstrating a trend towards superior effectiveness in the prevention of VTE. Amidine hydrochloride demonstrated a safety profile comparable to enoxaparin in relation to major and clinically significant non-major bleeding.

10 June 2021 in Kazan medical journal
Verified
Journal Article
Open access
PDF file
RKRoman E. Kalinin
Roman E. Kalinin
ISIgor Suchkov
Igor Suchkov
DMDenis A. Maksaev
Denis A. Maksaev
YAYulia Abalenikhina
Yulia Abalenikhina
Aim. To assess the antioxidant status in patients with secondary lymphedema of the lower extremities who undergo different types of conservative treatment. Methods. The study included 90 patients with secondary lymphedema of the lower extremities and 30 healthy volunteers. Group 1 participants (n=30) received compression therapy and Vitamin E at a dose of 400 IU/day, group 2 participants (n=30) compression therapy and a micronized purified flavonoid fraction 1000 mg/day, group 3 (n=30) compression therapy alone. Group 4 (n=30) comprised healthy volunteers. The level of malondialdehyde, the activity of superoxide dismutase, glutathione peroxidase, catalase, and the level of non-protein thiols (SH-groups) were determined at inclusion in the study and then after 1 and 3 months. Results. In patients with secondary lymphedema, the initial level of glutathione peroxidase was higher by 768.22%, catalase by 420.5%, malondialdehyde by 60%, and the level of SH-groups was lower by 65,71% compared with the group of volunteers. In the first group, there was a significant decrease of 36.1% in the level of superoxide dismutase and a significant increase of 89.9% in the level of glutathione peroxidase at the end of therapy when compared with the level after 1 month. In the second group, catalase level significantly increased by 33.3%, superoxide dismutase by 17.6%, and glutathione peroxidase by 61.3% compared to baseline values. The biochemical indicators of the endothelium significantly increased when using a combination of micronized purified flavonoid fraction and elastic compression in comparison with elastic compression alone and a combination with Vitamin E. In the third group, there were no significant differences in the levels of biochemical indicators of endothelial function. Conclusion. Increased formation of lipid peroxidation products along with a decrease in the activity of antioxidant systems was revealed in patients with lower extremity secondary lymphedema compared with healthy volunteers; the most effective therapy aimed at correcting endothelial cell dysfunction is the use of micronized purified flavonoid fraction and elastic compression.

15 December 2020 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
SASvetlana A. Anisimova
Svetlana A. Anisimova
JSJanna A. Svirina
Janna A. Svirina
DMDenis A. Maksaev
Denis A. Maksaev
Nowadays, hormonal imbalance is proven to be a factor that influences initiation of malignant and benign breast tumors. To study the aspects of participation of sex hormones in damage to organs and tissues, it may be necessary to model a common womens pathology fibrocystic disease of mammary glands characterized by the most pronounced effects of this pathogenetic factor, on experimental animals. Aim. To create a model of fibrocystic disease of mammary gland with the subsequent possibility of studying morphological manifestations of the disease in natural and drug-induced pathomorphism. Materials and Methods. The pathology was induced by intramuscular injection of 0.5 ml of 2% synestrol and 0.5 ml of 2.5% progesterone to virgin female rats on the 1st, 7th, 14th, 21st, 28th and 35th days of the experiment. For examination, histological preparations of inguinal mammary glands were made. The preparations were described and studied using morphometric analysis. Results. In the result of the experiment, pronounced macro- and microscopic alterations of mammary glands were found. Microscopic picture was similar to that observed in fibrocystic mastopathy in women. Almost all the morphometric parameters underwent reliable alterations in correspondence with the given pathology. Conclusion. A model of fibrocystic disease of mammary gland was obtained that may be used for further study of morphogenesis and methods of correction.